Breaking News

WuXi PharmaTech Tox Facility Passes Belgium Inspection

May 21, 2014

Suzhou site successfully passes three GLP inspections

WuXi PharmaTech’s toxicology facility in Suzhou has received a statement of Good Laboratory Practice (GLP) from the Belgium Scientific Institute of Public Health on behalf of the Organization for Economic Cooperation and Development (OECD). The facility passed three GLP inspections covering organizational processes and conditions under which health safety studies are planned, performed, monitored, recorded, archived, and reported.
 
The inspection audited 22 studies in areas that included general toxicology, genetic toxicology, safety pharmacology, dermal irritation, skin phototoxicity, and immunology.  
 
"The Belgian GLP statement for our toxicology facility is a further acknowledgment of the quality of our services, which meet the highest international standards," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "With this recognition, WuXi has further solidified its leadership in offering the highest-quality toxicology service in China. Toxicology is an important part of WuXi's comprehensive, fully integrated platform of services for our global and domestic pharmaceutical and biotech clients."

blog comments powered by Disqus
  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.